Esperance Pharmaceuticals develops anticancer drugs that kill cancer cells without harming normal cells.
Esperance Pharmaceuticals is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell's surface. The drugs kill even those cells known to be resistant to chemotherapeutic drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 1, 2011 | Series B | $7.50M | 3 | Sanofi | — | Detail |
Nov 24, 2008 | Series A | $3.20M | 1 | — | — | Detail |
Oct 31, 2006 | Series A | $9M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sanofi | Yes | Series B |
Advantage Capital | — | Series B |
Themelios Ventures | — | Series B |